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Objective: To compare in a generalizable sample/setting 
objective outcomes in patients receiving first-generation 
antipsychotic long-acting injectables (FGA-LAIs) or ris-
peridone-LAI (RIS-LAI). Methods: Nationwide, retro-
spective inception cohort study of adults with International 
Classification of Diseases-10 schizophrenia using Danish 
registers from 1995 to 2009 comparing outcomes between 
clinician’s/patient’s choice treatment with FGA-LAIs or 
RIS-LAI. Primary outcome was time to psychiatric hos-
pitalization using Cox-regression adjusting for relevant 
covariates. Secondary outcomes included time to all-
cause discontinuation and psychiatric hospitalization in 
patients without LAI possession gap >28 days, and num-
ber of bed-days after psychiatric hospitalization. Results: 
Among 4532 patients followed for 2700 patient-years, 
2078 received RIS-LAI and 2454 received FGA-LAIs 
(zuclopenthixol decanoate  =  52.2%, perphenazine dec-
anoate  =  37.2%, haloperidol decanoate  =  5.0%, flupen-
thixol decanoate = 4.4%, fluphenazine decanoate = 1.3%). 
RIS-LAI was similar to FGA-LAIs regarding time to 
hospitalization (RIS-LAI  =  246.2 ± 323.7  days vs FGA-
LAIs  =  276.6 ± 383.3  days; HR  =  0.95, 95% confidence 
interval (CI) = 0.87–1.03, P = 0.199) and time to all-cause 
discontinuation (RIS-LAI  =  245.8 ± 324.0  days vs FGA-
LAIs = 287.0 ± 390.9 days; HR = 0.93, 95% CI = 0.86–1.02, 
P = 0.116). Similarly, in patients without LAI discontinua-
tion, RIS-LAI and FGA-LAIs did not differ regarding time 
to hospitalization (RIS-LAI = 175.0 ± 268.1 days vs FGA-
LAIs = 210.7 ± 325.3 days; HR = 0.95, 95% CI = 0.86–
1.04, P = 0.254). Finally, duration of hospitalization was 
also similar (incidence rate ratio = 0.97, 95% CI = 0.78–
1.19, P  =  0.744). Results were unchanged when analyz-
ing only patients treated after introduction of RIS-LAI. 
Conclusions: In this nationwide cohort study, RIS-LAI was 
not superior to FGA-LAIs regarding time to psychiatric 
hospitalization, all-cause discontinuation, and duration of 
hospitalization. Given the cost of hospitalization and sec-
ond-generation antipsychotic (SGA)-LAIs, these findings 
require consideration when making treatment choices, but 
also need to be balanced with the individual relevance of 
adverse effects/patient centered outcomes. In future, head-
to-head trials and additional nationwide database studies 
including other SGA-LAIs is needed.
Key words:  schizophrenia/long-acting injectable/
risperidone/first-generation antipsychotics/
hospitalization/all-cause discontinuation/cohort study
Introduction
Despite treatment advances,1 schizophrenia remains one 
of the most disabling disorders.2 In addition to partial 
response and treatment refractoriness, relapses con-
tribute to the morbidity and mortality associated with 
schizophrenia.3,4 One established risk factor for inad-
equate treatment response and relapse is antipsychotic 
nonadherence.5 Nonadherence is frequent in all areas of 
medicine.6 However, for many reasons, including lack of 
insight, cognitive dysfunction, stigma, etc, patients with 
schizophrenia are at particular high-risk for nonadher-
ence.7 Measuring and identifying nonadherence is a 
challenge; underreporting is frequent and clinicians are 
generally poor in judging their patients’ adherence.5,7
While external reminders and psychosocial interven-
tions may improve nonadherence in schizophrenia,5,8 
long-acting injectable antipsychotics (LAIs) have been 
developed to address nonadherence through biweekly/
monthly injections. Although patients have to return 
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for injections, clinicians and family members are certain 
when a medication dose has been received or missed, 
allowing immediate action. Moreover, since LAIs release 
the medication slowly, missing an injection will not lead 
to a precipitous drop in the blood level like after stopping 
oral antipsychotics (OAPs), increasing the window of 
protection during which nonadherence can be addressed.
LAIs are considered an important treatment option 
for nonadherent patients.9 In a recent meta-analysis of 65 
randomized controlled trials (RCTs) lasting ≥6  months 
(n = 6493), both OAPs and LAIs were significantly supe-
rior to placebo in preventing relapses in schizophrenia.4 
Moreover, in an indirect comparison, LAIs (studies = 7) 
prevented relapse significantly more than OAPs (studies = 
14). However, results from studies directly comparing LAIs 
with OAPs are more complicated. For example, a recent 
meta-analysis of 5176 patients (studies = 21) found no dif-
ference between LAIs and OAPs.10 Nevertheless, the lack 
of superiority of LAIs was possibly due to factors inherent 
in RCTs that challenge the generalizability of these find-
ings, including recruitment of patients who are likely more 
adherent and less severely ill than those receiving LAIs in 
clinical practice, and whose adherence may be measured 
and is enhanced by frequent study visits or provision of 
OAPs.10 Supportive of this argument are results of a meta-
analysis of 25 mirror image studies (n = 5940), in which 23 
of the 25 studies individually showed LAI superiority for 
reducing hospitalizations in the same individuals switching 
from an OAP to LAI.11 However, one needs to consider that 
in mirror image studies in general, a time or order effect can 
affect outcomes and that in prospective mirror image stud-
ies participation in study procedures could bias results in 
favor of the second, LAI period. Support also comes from 
another meta-analysis in which pooling of results from 5 
RCTs did not show a difference between LAIs and OAPs 
regarding hospitalization, while in four mirror image studies 
and four cohort studies each LAIs were superior to OAPs.12 
Notably, nationwide cohort studies,13 included in the latter 
meta-analysis, have the strong advantage of giving a rep-
resentative picture of LAI effects under real-world condi-
tions. Although a nationwide naturalistic database includes 
treatment approaches that are and that are not guideline or 
evidence based, the interventions are used under conditions 
that reflect existing constraints, and the data base includes 
the entire cohort of treated patients, thereby providing a 
test of performance of the studied treatments in the envi-
ronment in which they will have to perform.
Although relapse and hospitalization are more 
cost-intensive than medications,14 second-generation 
antipsychotic (SGA)-LAIs are more expensive than 
first-generation antipsychotic (FGA)-LAI alternatives. 
Although the oversimplified dichotomy between FGAs 
and SGAs has likely outlived its utility,15 a finding from 
the most recent meta-analysis of RCTs of OAPs vs LAIs 
is of interest.10 Whereas pooled analyses did not show 
superiority of LAIs, analyzing FGA-LAIs and SGA-LAIs 
separately, FGA-LAIs were significantly superior to OAPs 
in preventing relapse (studies = 10, P = .02). Conversely, 
SGA-LAIs did not separate from OAPs (studies = 11, 
P = 1.0). Individually, too, neither olanzapine-LAI nor 
risperidone-LAI (RIS-LAI) were superior to OAPs regard-
ing relapse/other relapse-related outcomes. Nevertheless, the 
superiority of FGA-LAIs was moderated by publication 
year. In trials published until 1991, consisting exclusively of 
fluphenazine-LAI studies, LAIs were superior to OAPs (P = 
.02), while this was not the case in the newer RCTs published 
since 2005 (P = .94), which included only 2/10 FGA-LAI 
studies.10 However, these findings were based on an indirect 
comparison across several decades. Thus, findings could 
be due to time trends in the treatment and service delivery, 
including differences in patient illness severity, OAP com-
parator doses, thresholds for declaring relapse, etc, each 
potentially favoring LAIs in older trials. Therefore, direct 
comparisons of FGA-LAIs with SGA-LAIs are needed.10
In contrast to the LAI data reviewed above, two recent 
meta-analyses comparing oral SGAs with oral FGAs for 
relapse prevention and hospitalization in chronic3 and 
first-episode16 schizophrenia patients, each found signifi-
cant advantages for SGAs, albeit with modest effect sizes, 
translating into a number-needed-to-treat of 17.3 Since 
this difference could be due to worse adherence with oral 
FGAs due to greater extrapyramidal side effects, it is 
unclear if  relapse prevention advantages of SGAs would 
extend to LAI formulations.
The comparative effectiveness of expensive SGA-
LAIs vs cheaper FGA-LAIs is an important and largely 
unexamined question. Given health care cost pressures 
and the high personal and societal burden of relapses in 
schizophrenia and to overcome the bias inherent in RCTs 
examining this issue, we conducted a nationwide cohort 
study to assess the relative effects on relapse/hospitaliza-
tion of FGA-LAIs vs RIS-LAI, a widely used SGA-LAI. 
Based on the meta-analytic data on hospitalization risk 
with oral antipsychotics,3,16 we hypothesized that RIS-
LAI would be superior to FGA-LAIs regarding hospital-
ization and all-cause discontinuation.
Methods
Design
This was a retrospective inception cohort study using 
data from the nation-wide Danish registers. In Denmark, 
all diagnoses assigned throughout the country are 
reported to the Danish Central Psychiatric Research 
Register (DPCRR), which contains complete electronic 
data from 1969 onwards.17 The diagnostic validity of the 
schizophrenia diagnosis in the DPCRR has proven to be 
high, and the register has contributed significantly to epi-
demiological research.18,19
Ethical and data use approval for the study was 
approved by the Danish Data Protection Agency, 
National Board of Health and Statistics Denmark.
629
Comparative Effectiveness of Risperidone
Sample
Subjects for the analyses had a lifetime diagnosis of 
International Classification of Diseases (ICD-10 F20) 
schizophrenia in the DPCRR17 from January 1, 1995 
to December 31, 2009. All patients with schizophrenia 
filling ≥1 outpatient LAI prescription in Denmark dur-
ing the study period were included, as there is only one 
psychiatric health care system and all prescriptions are 
recorded in the national prescription database.
Treatment
Prescription data for included subjects were obtained 
from the national prescription database, containing 
information about the number of sold defined daily dos-
ages (DDD) of all outpatient prescription-based medi-
cations. DDDs are assigned and reviewed by researchers 
of the World Health Organization Collaborating Centre 
of Drug Statistics Methodology. Medication status dur-
ing inpatient treatment was not available. Only incident 
periods of FGA-LAIs or RIS-LAI were included in the 
analysis and all patients were followed for up to 5 years. 
Continued treatment was defined as renewing prescrip-
tion for the same LAI based on pack size, assuming that 
LAI injection intervals were 14 days and that each patient 
used one vial per injection. Saving remaining vials for a 
next injection or sharing prescription-based medicine 
between patients is not allowed in Denmark.
From 1995 to 2009, the following FGA-LAIs were 
available in Denmark: zuclopentixol-decanoate, haloper-
idol-decanoate, perphenazine-decanoate, fluphenazine-
decanoate, and flupenthixol-decanoate. RIS-LAI became 
available in Denmark in 2003. Only patients agreeing 
with LAIs were included, since no compulsory LAI treat-
ment was allowed in Denmark.
Outcomes
Primary outcome was time to psychiatric hospitalization; 
secondary outcome was time to all-cause discontinuation. 
Additionally, we compared RIS-LAI with FGA-LAIs 
regarding time to hospitalization in patients without LAI 
possession gap >28 days and number of bed-days after 
treatment failure for psychiatric hospitalization.
Time to Hospitalization
In the time to psychiatric hospitalization model, patients 
were censored at death, after 5 years follow-up, switch 
between LAI treatments or filling an OAP prescrip-
tion after a ≥2-week gap of filling the LAI prescription, 
whichever came first. The latter censoring criterion was 
used to censor patients who were switched intentionally, 
by patient’s or the prescriber’s decision, to oral treatment. 
For the sensitivity analysis of patients with hospitaliza-
tion before LAI discontinuation patients were censored 
when the LAI possession gap exceeded 28 days.
Time to All-Cause Discontinuation
Time to all-cause discontinuation was chosen as a combined 
outcome, reflecting both patient’s/family’s and prescriber’s 
decisions for discontinuation, including inefficacy, intolera-
bility, nonadherence, and non-medication related factors. An 
additional 14-day gap between injections was allowed before 
patients were considered as having discontinued the LAI. 
Patients switched from one FGA-LAI to another FGA-LAI 
were considered as having discontinued treatment.
Covariates
The following covariates were used to adjust for confound-
ing by indication or severity of schizophrenia: illness dura-
tion, sex, time of LAI initiation, percentage of time with 
psychiatric hospitalization during the last 2 years, receiv-
ing disability pension, prior clozapine use, number of 
psychiatric and non-psychiatric co-medications, and LAI 
initiation during inpatient vs outpatient status. Initiating 
LAIs during inpatient status was defined as patients pick-
ing up their first LAI prescription within 4 weeks after 
hospital discharge. Adjustment for dose variation among 
individuals was not possible because with FGA-LAIs the 
full vial content is not necessarily injected.
Since OAP treatment is common during LAI treatment 
and may affect the outcome, we adjusted for OAP cotreat-
ment in regression models. However, the first 2 months 
were excluded from creating this covariate because it is 
recommended to use oral risperidone for ≥3 weeks after 
the first RIS-LAI injection due to delayed absorption. 
Furthermore, we specified whether a different or the same 
OAP compared to the LAI was used adjunctively, as the 
former may reflect lack of LAI monotherapy efficacy or 
attempt to reduce adverse effects, whereas as the latter 
more likely reflects the need for quick dose adjustment. 
We reported both rates of patients filling only one pre-
scription from the pharmacy and rates of patients filling 
≥2 prescriptions during the study period.
The number of non-antipsychotic psychiatric co-med-
ications at baseline during the first 3 months was defined 
as picking up at least one prescription of the following 
drugs/drug groups: antidepressants (N06A+N06C), 
stimulants (N06B), anti-dementia drug (N06D), clon-
azepam (N03AE01), valproate (N03AG01), lamotrigine 
(N03AX09), carbamazepine (N03AF01), oxcarbazepine 
(N03AF02), lithium (N05AN), and psycholeptics (anxio-
lytics, sedatives, anxiolytics) (N05B+N05C).
The number of non-psychiatric medications was 
defined as any other drug not listed above. 
Since RIS-LAI was not available before 2003, RIS-LAI 
patients entered the survival analysis later than FGA-
LAI patients. Since hospitalization depends on multiple 
factors, we assessed secular trends in number of psychi-
atric hospitalizations, bed-days, and interval between 
hospitalizations (truncated at the maximum follow-up 
time of this study = 5 years) for all Danish schizophrenia 
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patients (ICD-10 F20) during the years 1995–2009 
(n = 26 230). During the study period, both the number of 
admissions and time to hospitalization increased, while 
the number of bed-days decreased significantly (Table 1). 
Therefore, we added year of LAI initiation as a covari-
ate in all regression analyses. In addition, we conducted 
a sensitivity analysis only including patients entering the 
analysis from 2003 onwards.
Statistical Analyses
Statistical analyses were performed with STATA 12 at 
Statistics Denmark server via remote access. Sample 
characteristics were compared between RIS-LAI and 
FGA-LAIs using Student’s t test or Wilcoxon rank sum 
test, whichever appropriate, for continuous variables, and 
using chi-squared test for categorical variables. For all 
survival analyses, a Cox-regression survival analysis was 
conducted to obtain hazard ratios (HR) with 95% con-
fidence intervals (CI) indicating risk modeled as time to 
the respective event. All models were tested for propor-
tional hazards with estat phtest commands in STATA, 
which used the residuals of Schoenfeld, and were evalu-
ated graphically. The covariates listed above were used as 
explanatory variables aiming to identify relevant modera-
tors of the respective outcomes. Countable data, such as 
number of bed-days after treatment failure for psychiatric 
admission were compared between RIS-LAI and FGA-
LAIs using negative binomial regression analysis and the 
same covariates as above because of the overdispersed 
distribution, which is common in observational studies 
reflecting sample heterogeneity.
Results
A total of 4532 patients initiating LAIs were identified; 
2078 (45.9%) initiated RIS-LAI and 2454 (54.1%) initi-
ated FGA-LAIs. Total follow-up time was 4700 patient-
years. Sample characteristics are shown in Table  2. 
Compared with patients initiating FGA-LAIs, RIS-LAI 
patients were younger (35.8 ± 12.5 vs 39.0 ± 13.4 years, 
P < .001) and more male (59.6% vs 55.6%, P = .006). 
Additionally, RIS-LAI patients had characteristics asso-
ciated with less illness severity than FGA-LAI users (eg, 
lower percentage of prior inpatient time, less patients 
receiving disability pension and living in an institution), 
except for longer duration of schizophrenia diagnosis (P 
< .001). Moreover, patients on RIS-LAI had more outpa-
tient contacts per month (1.8 ± 2.4 vs 1.2 ± 1.9, P < .001).
Time to Psychiatric Hospitalization
RIS-LAI was not different from FGA-LAIs in adjusted 
Cox regression analyses regarding time to hospitaliza-
tion in all patients (2710.9 patient-years: HR = 0.95, 
95% CI = 0.87–1.03, P = .199) (Table 3, Figure 1) and in 
patients without prespecified LAI possession gap (1691.1 
patient-years: HR = 0.95, 95% CI = 0.86–1.04, P = .254) 
(Table 3). In the sensitivity analysis of patients first ini-
tiating LAI treatment after 2003, RIS-LAI was also not 
superior to FGA-LAI (HR = 1.03, 95% CI = 0.93–1.13, 
P = .572) (Table 4).
Time to All-Cause Discontinuation
RIS-LAI was not significantly different from FGA-
LAIs regarding time to all-cause discontinuation (2892.7 
patient-years: HR = 0.94, 95% CI = 0.86–1.02, P = .116) 
(Table 3, Figure 1). Sensitivity analyses were consistent 
with the primary results (HR = 1.01, 95% CI = 0.92–1.11, 
P = .839) (Table 4).
Number of Bed-Days After Failure Due to Psychiatric 
Hospitalization
Number of bed-days was significantly higher in the FGA-
LAI group, 233.4 (463.6) vs 159.6 (SD = 294.7). However, 
in the adjusted binomial regression analyses, RIS-LAI 
and FGA-LAIs did not differ regarding the duration of 
hospitalization (IRR = 0.97 95% CI = 0.78–1.19, P = 
.744) (Table 3). Sensitivity analyses were consistent with 
the primary results (IRR = 1.06, 95% CI = 0.84–1.32, P 
= .632) (Table 4).
Discussion
This is the largest study to investigate the real-world 
effects of RIS-LAI, the first and most used SGA-LAI, 
Table 1. Secular Trends in Psychiatric Admissions and Bed Days 
Based on 26 230 Schizophrenia Patients
Year
Admissions Bed Days
Days Between Last 
Discharge and New 
Admission
Mean 95% CI Mean 95% CI Meana 95% CI
1995 1.77 1.74–1.81105.2 104.9–105.5 402.8 402.2–403.4
1996 1.87 1.84–1.91103.1 102.8–103.3 390.3 389.7–390.9
1997 1.83 1.79–1.86105.1 104.9–105.4 393.9 393.3–394.5
1998 1.88 1.85–1.91102.2 101.9–102.4 408.3 407.7–408.9
1999 1.93 1.89–1.96100.9 100.6–101.1 380.4 379.8–381.0
2000 1.87 1.84–1.91 97.0 96.7–97.2 411.7 411.1–412.3
2001 1.96 1.92–1.99 91.4 91.1–91.6 392.4 391.9–393.0
2002 1.97 1.93–2.00 91.0 90.8–91.2 414.3 413.8–414.9
2003 1.93 1.90–1.97 86.8 86.6–87.1 427.9 427.4–428.5
2004 1.94 1.91–1.98 84.9 84.7–85.1 431.0 430.4–431.5
2005 1.96 1.92–1.99 81.1 80.9–81.3 459.2 458.6–459.8
2006 2.01 1.97–2.04 79.4 79.2–79.6 452.8 452.2–453.4
2007 2.08 2.05–2.12 77.8 77.6–78.0 461.8 461.2–462.4
2008 2.19 2.15–2.23 74.5 74.3–74.7 433.0 432.5–433.6
2009 2.27 2.23–2.31 70.8 70.6–71.0 443.9 443.3–444.4
Slopeb 0.01 P < .001 −0.03 P < .001 0.01 P < .001
Note: aWith values truncated at 5 years (1826 days).
bEstimated from negative binomial regression analyses using 
calendar year as explanatory variable.
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compared to FGA-LAIs regarding the important out-
comes of relapse/hospitalization and duration of hos-
pitalization in schizophrenia. Our major finding is that, 
contrary to our hypotheses, RIS-LAI was not superior to 
FGA-LAIs regarding time to hospitalization, adjusting 
for relevant covariates and taking into account whether 
or not patients stopped filling LAI prescriptions, regard-
ing time to all-cause discontinuation and duration of 
hospitalization after treatment failure. Additionally, as 
described before,20,21 many patients discontinued treat-
ment and/or relapsed early after initiating LAIs. In a 
previous data base study of schizophrenia patients, the 
mean duration of LAI treatment episodes was only 71.7 
± 56.4  days for haloperidol-LAI, 58.3 ± 53.6  days for 
fluphenazine-LAI, and 60.6 ± 48.8 days for RIS-LAI.21
Since number of hospitalizations increased during 
the latter part of the study and since patients on RIS-
LAI had longer illness duration, the lack of superiority 
of RIS-LAI compared to FGA-LAIs could be due to a 
greater likelihood of admissions in the later years or due 
to greater illness chronicity. However, we adjusted the 
Cox-regression analyses for year of initiating LAI and 
illness duration, and RIS-LAI patients also had charac-
teristics pointing toward lower illness severity and risk 
Table 2. Sample Characteristics
Total (N = 4532)
Risperidone-LAI 
(N = 2078)
Conventional-LAI 
(N = 2454)
P ValueMean SD Mean SD Mean SD
Age, years
 Onset of any psychiatric disorder 28.5 11.1 27.4 10.4 29.5 11.6 <.001
 Onset of schizophrenia 35.0 13.2 32.7 12.3 37.0 13.7 <.001
 Baseline (entering the survival analysis) 37.5 13.1 35.8 12.5 39.0 13.4 <.001
 Male sex (N, %) 2603 57.4 1239 59.6 1364 55.6 .006
 Started as inpatient (N, %) 298 6.6 125 6.0 173 7.1 .162
 Year of initiation 2003.1 4.1 2005.9 1.9 2000.7 4.0 <.001
  Percentage of time with psychiatric hospitalization  
(2 years prior of LAI initiation)
0.3 0.4 0.3 0.3 0.4 0.4 <.001
Duration of illness (years)
 From onset of schizophrenia diagnosis 2.5 2.9 3.1 3.2 2.0 2.6 <.001
 From onset of first psychiatric diagnosis 9.0 8.2 8.4 7.8 9.6 8.5 <.001
 Receiving disability pension (N, %) 2943 64.9 1225 59.0 1718 70.0 <.001
 Exposure to clozapine (N, %) 374 7.1 181 8.7 193 7.9 .303
 Mean number of outpatient contacts per month 1.5 2.2 1.8 2.4 1.2 1.9 <.001
 Married (N, %) 321 7.1 93 4.5 228 9.3 <.001
Living situation (N, %)
 Alone 2897 63.9 1078 51.9 1819 74.1 <.001
 In institution 459 10.1 142 6.8 317 12.9 <.001
Concomitant medications (N, %)
 Non-psychiatric medications 1.5 2.2 1.2 2.0 1.8 2.3 <.001
 Psychiatric co-medications 0.9 1.1 0.9 1.1 0.9 1.1 .550
 Any oral antipsychotic after 2 months (N, %)a 1342 44.3 626 45.2 716 43.6 .377
 Same oral antipsychotic as intervention 554 18.3 298 21.5 256 15.6 <.001
 Other oral antipsychotic than intervention 1032 34.1 454 32.8 578 35.2 .165
 Any oral antipsychotic (min. 2 pick-ups) after 2 months (N, %)a 1100 36.3 513 37.0 587 35.7 .459
 Same oral antipsychotic as intervention (min. 2 pick-ups) 385 12.7 208 15.0 177 10.8 .001
 Other oral antipsychotic than intervention (min. 2 pick-ups) 855 28.2 367 26.5 488 29.7 .051
Antipsychotic DDD’s (oral and LAI) last year before baselineb
 Total 0.98 1.10 0.95 1.15 1.01 1.06 <.001
 Adjusted for number of bed-days 1.57 1.98 1.29 1.60 1.83 2.24 <.001
Type of first-generation antipsychotic long-acting injectable (N, %)
 Fluphenazine decanoate — — 31 1.3 —
 Perphenazine decanoate — — 912 37.2 —
 Haloperidol decanoate — — 123 5.0 —
 Flupentixol decanoate — — 107 4.4 —
 Zuclopenthixol decanoate — — 1281 52.2 —
Note: FGA-LAI, first-generation antipsychotic long-acting injectable.
aIn total, 3027 patients “survived” the first 2 months. The risperidone group includes 1385 patients, and the conventional group 
includes1642 patients. Percentages are calculated based on these groups.
b152 patients from the conventional group were excluded because 1-year follow-up before baseline was not possible. Calculation is based 
on N = 2302.
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for hospitalization, including lower percentage of prior 
inpatient time, less patients receiving disability pension 
and living in an institution, factors we also adjusted for. 
Moreover, even when restricting the analyses to patients 
initiating LAI treatment from 2003 onwards when RIS-
LAI was available yielded similar results as the main 
analyses.
Although the similar hospitalization risk of RIS-LAI 
and FGA-LAIs is consistent with results of broadly similar 
efficacy of oral antipsychotics for schizophrenia,15,22,23 our 
results are in contrast to two recent meta-analyses that did 
show significant advantages of oral SGAs vs oral FGAs for 
relapse prevention/hospitalization.3,16 However, these meta-
analyses were also based on RCTs that include only a subset 
of patients treated nationwide, and samples were obvi-
ously much smaller than in this register study. Moreover, 
although multiple open label studies had shown advantages 
of a switch from OAPs or FGA-LAIs to RIS-LAI,24–27 supe-
riority of RIS-LAI over OAPs was not confirmed in the 
previously mentioned meta-analysis.10 Similarly, superiority 
of switch to RIS-LAI over remaining on FGA-LAIs was 
also not confirmed in an RCT randomizing 66 adults with 
schizophrenia or schizoaffective disorder taking haloperi-
dol-LAI (n = 40) or fluphenazine-LAI (n = 22) to stay on 
these LAIs or switch to RIS-LAI.28 In analyses of the first 
6 months conducted under protocol conditions, time to all-
cause discontinuation was similar between the switch and 
stay groups. Conversely, including the subsequent 6-month 
naturalistic phase, patients switched to RIS-LAI stopped 
treatment earlier than those staying on FGA-LAIs (31% 
vs 10%, P = .01). LAI groups also did not differ regarding 
psychopathology, hospitalizations, sexual side effects, and 
new-onset tardive dyskinesia or extrapyramidal symptoms, 
while those switched to RIS-LAI had significantly greater 
increases in body mass index and prolactin.28 Moreover, 
our findings are consistent with similar rehospitalization 
rates associated with RIS-LAI (29.4%) and FGA-LAIs 
(28.2%) in a small subsample of patients with first epi-
sode schizophrenia discharged on an LAI (RIS-LAI: N = 
51; FGA-LAIs: N = 77) in a nationwide Finnish sample.13 
Although the hospitalization rates were lower than in our 
study, this is likely due to the fact that discontinuation was 
more frequent (RIS-LAI = 78.4%, FGA-LAIs = 98.7%). 
Additionally, our results  in patients treated under natural-
istic conditions are also consistent with the first, recently 
published, head-to-head, randomized controlled trial that 
compared paliperidone-LAI with haloperidol-LAI.29 This 
study found that during follow-up of up to 24 months, 
both treatments had similar efficacy failure, defined as a 
psychiatric hospitalization, need for crisis stabilization, and 
substantial increase in frequency of outpatient visits, clini-
cian’s decision that oral antipsychotics could not be dis-
continued within 8 weeks after LAI initiation, or clinician’s 
decision to discontinue the assigned LAI due to inefficacy. 
Nevertheless, both treatments differed significantly regard-
ing some adverse effects.29
Table 3. Cox Regression and Negative Binomial Regression Analysis Results
Time to Hospitalization 
(All Patients)
Time to All-Cause 
Discontinuation
Time to Hospitalization 
(Patients Without LAI 
possession Gap >28 Days)
Number of Bed-Days 
After Failure for 
Hospitalization
N = 4532 (3765 Failures) N = 4532 (3933 Failures) N = 4532 (3157 Failures) N = 3765
2710.9 patient-years 2892.7 patient-years 1691.1 patient-years N/A
HRa 95% CI P Value HRa 95% CI P Value HRa 95% CI P Value IRRb 95%CI P Value
Risperidone 0.95 0.87–1.03 .199 0.94 0.86–1.02 .116 1.03 0.93–1.15 .519 0.97 0.78–1.19 .744
Male sex 1.04 0.97–1.11 .274 1.04 0.98–1.12 .208 0.95 0.87–1.05 .302 1.12 0.96–1.30 .163
Year of depot initiation 1.01 1.00–1.02 .126 1.01 1.00–1.02 .055 1.08 1.05–1.11 <.001 0.93 0.91–0.96 <.001
Percentage of time with 
psychiatric hospitalization 
during 2 years prior to  
LAI intiation
1.93 1.75–2.13 <.001 1.88 1.71–2.06 <.001 2.19 1.88–2.55 <.001 7.23 5.81–9.00 <.001
Duration of illness 1.97 1.88–2.06 <.001 1.92 1.84–2.01 <.001 2.17 2.00–2.35 <.001 1.15 1.11–1.19 <.001
Disability pension 1.00 0.93–1.07 .903 1.00 0.94–1.08 .908 1.08 0.97–1.19 .159 1.18 1.00–1.39 .044
Clozapine 1.23 1.09–1.38 .001 1.20 1.07–1.35 .002 1.29 1.10–1.51 .002 2.46 1.90–3.19 <.001
Number of non-psychiatric 
medications
0.94 0.92–0.95 <.001 0.95 0.93–0.96 <.001 0.93 0.91–0.95 <.001 0.92 0.90–0.94 <.001
Number of psychiatric 
co-medications
1.07 1.03–1.10 <.001 1.06 1.03–1.10 <.001 1.07 1.03–1.12 <.001 0.83 0.77–0.89 <.001
Inpatient status at time of 
LAI initiation
0.75 0.64–0.88 <.001 0.77 0.66–0.90 .001 0.75 0.62–0.90 .002 0.85 0.63–1.16 .319
Note: IRR, incidence rate ratio.
aCox regression analysis.
bNegative binomial regression analysis, IRR.
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The mean age of onset of schizophrenia was rather 
high compared to other studies, which is explained by the 
fact that most of these patients were diagnosed in the past 
when less focus existed on early diagnosis and interven-
tion. The age of onset of schizophrenia has been reduced 
substantially during the last decade in Denmark.30 
Moreover, we did not employ an upper age limit for first 
episode schizophrenia as used in most other first episode 
studies.
More than half  of the patients in the FGA-LAI group 
were treated with zuclopenthixol-decanoate, which is 
not marketed in the US, but widely used in Scandinavia 
and UK. Since zuclopenthixol is an FGA,31 the observed 
similar outcomes with FGA-LAIs was unlikely driven 
by unique efficacy of zuclopenthixol-LAI. Actually, one 
open study of 435 patients even suggested superiority 
of RIS-LAI regarding treatment persistence vs zuclo-
penthixol-LAI (P = .002) and all other FGA-LAIs (P = 
.009),32 yet the samples were small and relevant covariates 
were not controlled for.
Expectedly, significant moderators of shorter time to 
hospitalization and higher all-cause discontinuation in 
the Cox-regression models included proxy measures of 
illness severity, including illness duration, percentage of 
time hospitalized in the preceding 2 years, higher num-
ber of psychotropics, and previous clozapine treatment. 
Conversely, variables associated with more supervision/
health contact, such as initiating LAIs as an inpatient 
and higher number of non-psychiatric medications, were 
associated with a reduced likelihood of hospitalization 
and all-cause discontinuation.
Strengths of this study are its large sample and gener-
alizability, including all schizophrenia patients initiating 
LAIs nationwide, many of which would be too sick or 
unwilling to participate in research, illustrated by the fact 
that >40% were hospitalized and 60% discontinued LAI 
within 6 months.
Despite its strengths, this study also has limitations. 
First, treatment allocation was not random. Therefore, 
risks of biases exist, such as difference in illness sever-
ity and effects of secular trends. Although there might 
be additional biases, we adjusted for many, if  not most, 
relevant biases. Second, psychopathology, functional/
quality of life and side-effect ratings, including tardive 
dyskinesia, were not available. Therefore, we cannot rule 
out that either RIS-LAI or FGA-LAIs may have advan-
tages within some of these domains. Third, we assumed 
that each vial was equivalent to 14  days treatment, the 
main recommendation for all LAIs used in this study. 
Although, FGA-LAIs are traditionally administered 
biweekly in Denmark, some FGA-LAIs may have been 
administered every 3 or 4 weeks, which could have led to 
erroneous pronouncement of early termination, favoring 
RIS-LAI. Fourth, time of discontinuation was based on 
when LAIs were not filled from the pharmacy anymore. 
However, some patients may have stopped the LAI before 
using all vials, leading to overestimating the time until 
discontinuation. This might explain why the proportion 
of patients without a >28 day LAI possession gap at time 
of admission was rather high. Fifth, discontinuation rates 
in this study were higher than in some prior studies. This 
difference may be partly due to the fact that this study 
was a nationwide study including even the most severe 
patients. In addition, we focused in this inception cohort 
study on the incident LAI period. This approach may also 
have contributed to the results, as we included patients 
earlier in their illness course than most studies (mean age 
= 28 years) when nonadherence may be somewhat higher. 
Sixth, RIS-LAI was introduced during the second half  
of the study. This may have influenced findings through 
secular trend effects. Over the years, inpatient treatment 
shifted to outpatient services, as documented previously,30 
illustrated also by the lower number of bed-days and lon-
ger time between admissions. This shift to ambulatory 
care may have favored RIS-LAI in the time to psychiatric 
hospitalization model because of a higher threshold for 
admission. However, we adjusted Cox-regression analyses 
for time of study entry and results remained unchanged 
when restricting the analyses to patients treated after 
Fig. 1. Survival analysis curve of time to psychiatric hospitalization 
and time to all-cause discontinuation.
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introduction of RIS-LAI into the Danish market. 
Additionally, RIS-LAI patients received more outpatient 
contacts during their follow-up because of the secular 
trend toward more treatment during outpatient status.30 
This may have favored patients entering the study in the 
last half  of the study period. Seventh, we did not have 
access to reasons for discontinuation, which could have 
highlighted potential differences in efficacy or tolerability 
or which could have included switch to the new RIS-LAI 
in stable patients, as RIS-LAI had been touted as being 
superior and/or better tolerated than FGA-LAIs.24–26 The 
latter motivation, would have favored RIS-LAI regard-
ing all-cause discontinuation. Finally, the database con-
tained RIS-LAI as the sole SGA-LAI. However, since 
RIS-LAI was either non-inferior to paliperidone-LAI33 
or outperformed paliperidone-LAI using a prespecified 
5.5 point non-inferiority margin,34 results may generalize 
to other SGA-LAIs, at least those with similar pharma-
cology, bearing in mind that among SGAs risperidone is 
closest to FGAs in its receptor binding profile and side 
effect propensity. The same applies to paliperidone LAI, 
which has recently been studied finding no differences 
compared to haloperidol-LAI.29
Although this study was not designed as a cost-effec-
tiveness study, the study results should also be interpreted 
in the light of the cost of medication and psychiatric 
hospitalization. During the study period, the annual cost 
for RIS-LAI was approximately 7500 USD compared to 
300 USD for FGA-LAIs. The costs for a psychiatric hos-
pitalization was approximately 700 USD per day. The raw 
figures suggest that in Denmark FGA-LAIs would be 
more cost effective until up to 10 bed-days per year more 
than RIS-LAI patients. Obviously, this ratio will be dif-
ferent in different countries and settings, as it depends on 
the medication and inpatient cost that vary considerably. 
Moreover, the value of a cost-derived number of an addi-
tional 10  days per year that FGA-LAI treated patients 
could spend in the hospital without their care being more 
expensive than that of RIS-LAI treated patients needs 
to be evaluated vis-à-vis personal suffering during hos-
pitalization and detrimental effects of relapse. Studies 
specifically investigating the cost effectiveness of SGA-
LAIs vs FGA LAIs based on large naturalistic studies 
are warranted.
In conclusion, despite a 30-day longer time until hospi-
talization and 40-day longer time until all-cause discon-
tinuation with RIS-LAI than FGA-LAIs over the entire 
treatment period, results were not statistically different 
between the two treatment groups, and this difference is of 
questionable clinical relevance. Moreover, although hos-
pitalization days were 74 days shorter for RIS-LAI, this 
difference was also clearly not different (IRR = 0.97, P = 
Table 4. Sensitivity Analysis of Subjects Only Entering From 2003 or Later: Cox Regression and Negative Binomial Regression Analysis 
Results
Time to Hospitalization 
(All Patients)
Time to All-Cause 
Discontinuation
Time to Hospitalization 
(Patients Without LAI 
possession Gap >28 
Days)
Number of Bed-Days After 
Failure for Hospitalization
N = 2854 (2290 Failures) N = 2854 (2404 Failures) N = 2854 (1890 Failures) N = 2290
1563.9 patient-years 1660.7 patient-years 966.3 patient-years N/A
HRa 95% CI P Value HRa 95% CI P Value HRa 95% CI P Value IRRb 95% CI P Value
Risperidone 1.03 0.93–1.13 .572 1.01 0.92–1.11 .839 0.95 0.86–1.04 .254 1.06 0.84–1.32 .632
Male sex 0.97 0.89–1.06 .474 0.98 0.90–1.06 .586 1.04 0.96–1.12 .323 1.10 0.91–1.34 .334
Year of depot initiation 1.08 1.05–1.11 <.001 1.07 1.05–1.10 <.001 1.01 1.00–1.02 .256 0.92 0.88–0.97 .002
Percentage of time with 
psychiatric hospitalization 
during 2 years prior to  
LAI initiation
2.03 1.77–2.32 <.001 1.95 1.71–2.22 <.001 2.05 1.84–2.28 <.001 9.24 6.92–12.32 <.001
Duration of illness 1.89 1.78–2.01 <.001 1.87 1.76–1.98 <.001 2.28 2.15–2.42 <.001 1.15 1.11–1.19 <.001
Disability pension 1.03 0.94–1.14 .476 1.03 0.94–1.13 .473 1.03 0.95–1.11 .497 1.13 0.92–1.40 .235
Clozapine 1.23 1.06–1.42 .005 1.19 1.03–1.38 .016 1.27 1.12–1.44 <.001 3.20 2.35–4.36 <.001
Number of non-psychiatric 
medications
0.93 0.91–0.96 <.001 0.95 0.93–0.97 <.001 0.93 0.91–0.95 <.001 0.82 0.78–0.85 <.001
Number of psychiatric 
co-medications
1.08 1.04–1.12 <.001 1.07 1.03–1.12 <.001 1.07 1.03–1.12 .002 0.80 0.73–0.89 <.001
Inpatient status at time of 
LAI initiation
0.72 0.58–0.90 .004 0.76 0.61–0.94 .010 0.73 0.56–0.94 .014 0.77 0.51–1.16 .207
Note: IRR, incidence rate ratio.
aCox regression analysis.
bNegative binomial regression analysis, IRR.
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.744) when potentially confounding variables were entered 
into the analyses. This lack of difference in clinically rel-
evant outcomes found in over 4500 patients, coupled 
with the higher cost for RIS-LAI and other SGA-LAIs, 
requires consideration when making treatment decisions. 
However, these findings should also be considered with 
the limitations of our study in mind, including its non-
randomized nature, lack of information on reasons for 
discontinuation, adverse effects, quality of life, subjec-
tive well-being, caregiver assessment of patients’ status, 
the observed group differences in baseline and outpatient 
contact characteristics, the potential influence of secular 
trends over time with RIS-LAI being only available start-
ing in 2003, and inclusion of FGA-LAIs not available in 
all parts of the world as well as inclusion of RIS-LAI as 
the sole SGA-LAI. Therefore, additional, large, simple, 
randomized trials are needed that evaluate the efficacy, 
tolerability and effectiveness of specific LAIs in the treat-
ment of generalizable patient cohorts with schizophrenia 
who are managed in usual care environments.
Funding
This study was unfunded.
Acknowledgments
J.N. has received research grants from H. Lundbeck, Pfizer 
and Chempaq for clinical trials and received speaking fees 
from Bristol-Myers Squibb, Astra Zeneca, Lundbeck, 
Janssen Pharmaceutica, and Hemocue. S.O.W.J., J. B.V. and 
R.F. have no financial disclosures. C.U.C. has been a consul-
tant, advisor, lecturer and/or data safety monitor to or has 
received honoraria from: Actelion, Alexza; AstraZeneca, 
Biotis, Bristol-Myers Squibb, Cephalon, Desitin, Eli 
Lilly, Genentech, Gerson Lehrman Group, Glaxo Smith 
Kline, IntraCellular Therapies, Lundbeck, Medavante, 
Medscape, Merck, National Institute of Mental Health, 
Novartis, Ortho-McNeill/Janssen/J&J, Otsuka, Pfizer, 
ProPhase, Roche, Schering-Plough, Sepracor/Sunovion, 
Takeda, Teva and Vanda. He has received grant support 
from Bristol-Myers Squibb, Feinstein Institute for Medical 
Research, Janssen/J&J, National Institute of Mental Health 
(NIMH), National Alliance for Research in Schizophrenia 
and Depression (NARSAD), and Otsuka. He has been a 
Data Safety Monitoring Board member for Bristol-Myers 
Squibb, Cephalon, Eli Lilly, Janssen, Lundbeck, Otsuka, 
Pfizer, Takeda, and Teva.
References
 1. Kane JM, Correll CU. Past and present progress in the 
pharmacologic treatment of schizophrenia. J Clin Psychiat. 
2010;71:1115–1124.
 2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with dis-
ability (YLDs) for 1160 sequelae of 289 diseases and injuries 
1990–2010: a systematic analysis for the Global Burden of 
Disease Study 2010. Lancet. 2012;380:2163–2196.
 3. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll 
CU. Relapse prevention in schizophrenia: a systematic review 
and meta-analysis of second-generation antipsychotics versus 
first-generation antipsychotics. Mol Psychiat. 2013;18:53–66.
 4. Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs ver-
sus placebo for relapse prevention in schizophrenia: a system-
atic review and meta-analysis. Lancet. 2012;379:2063–2071.
 5. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert con-
sensus guideline series: adherence problems in patients 
with serious and persistent mental illness. J Clin Psychiat. 
2009;70(suppl 4):1–46; quiz 47–48.
 6. Cramer JA, Rosenheck R. Compliance with medication 
regimens for mental and physical disorders. Psychiatr Serv. 
1998;49:196–201.
 7. Kane JM, Kishimoto T, Correll CU. Non-adherence to 
medication in patients with psychotic disorders: epidemiol-
ogy, contributing factors and management strategies. World 
Psychiatry. 2013;12:216–226.
 8. Velligan D, Mintz J, Maples N, et al. A randomized trial com-
paring in person and electronic interventions for improving 
adherence to oral medications in schizophrenia. Schizophrenia 
Bull. 2013;39:999–1007.
 9. Velligan DI, Weiden PJ, Sajatovic M, et  al. Strategies for 
addressing adherence problems in patients with serious and 
persistent mental illness: recommendations from the expert 
consensus guidelines. J Psychiatr Pract. 2010;16:306–324.
 10. Kishimoto T, Robenzadeh A, Leucht C, et  al. Long-acting 
injectable vs oral antipsychotics for relapse prevention 
in schizophrenia: a meta-analysis of randomized trials. 
Schizophr Bull. 2014;40:192–213.
 11. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. 
Long-acting injectable versus oral antipsychotics in schizo-
phrenia: a systematic review and meta-analysis of mirror-
image studies. J Clin Psychiatry. 2013;74:957–965.
 12. Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effec-
tiveness of depot versus oral antipsychotics in schizophrenia: 
synthesizing results across different research designs. J Clin 
Psychiatry. 2013;74:568–575.
 13. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, 
Korhonen P. A nationwide cohort study of oral and depot 
antipsychotics after first hospitalization for schizophrenia. 
Am J Psychiatry. 2011;168:603–609.
 14. Mangalore R, Knapp M. Cost of schizophrenia in England. 
J Ment Health Policy Econ. 2007;10:23–41.
 15. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy 
and tolerability of 15 antipsychotic drugs in schizophrenia: a 
multiple-treatments meta-analysis. Lancet. 2013;382:951–962.
 16. Zhang JP, Gallego JA, Robinson DG, Malhotra AK, Kane 
JM, Correll CU. Efficacy and safety of individual second-
generation vs. first-generation antipsychotics in first-epi-
sode psychosis: a systematic review and meta-analysis. Int J 
Neuropsychopharmacol. 2013;16:1205–1218.
 17. Mors O, Perto GP, Mortensen PB. The Danish Psychiatric 
Central Research Register. Scand J Public Health. 
2011;39:54–57.
 18. Uggerby P, Østergaard SD, Røge R, Correll CU, Nielsen J. 
The validity of the schizophrenia diagnosis in the Danish 
Psychiatric Central Research Register is good. Dan Med J. 
2013;60:A4578.
 19. Uggerby P, Nielsen RE, Correll CU, Nielsen J. Characteristics 
and predictors of long-term institutionalization in patients 
with schizophrenia. Schizophr Res. 2011;131:120–126.
636
J. Nielsen et al
 20. Mohamed S, Rosenheck R, Harpaz-Rotem I, Leslie D, 
Sernyak MJ. Duration of pharmacotherapy with long-act-
ing injectable risperidone in the treatment of schizophrenia. 
Psychiatr Q. 2009;80:241–249.
 21. Olfson M, Marcus SC, Ascher-Svanum H. Treatment of 
schizophrenia with long-acting fluphenazine, haloperidol, or 
risperidone. Schizophr Bull. 2007;33:1379–1387.
 22. Lieberman JA, Stroup TS, McEvoy JP, et  al.; Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) 
Investigators. Effectiveness of antipsychotic drugs in 
patients with chronic schizophrenia. N Engl J Med. 
2005;353:1209–1223.
 23. Jones PB, Barnes TR, Davies L, et al. Randomized controlled 
trial of the effect on Quality of Life of second- vs first-gen-
eration antipsychotic drugs in schizophrenia: Cost Utility 
of the Latest Antipsychotic Drugs in Schizophrenia Study 
(CUtLASS 1). Arch Gen Psychiatry. 2006;63:1079–1087.
 24. Lasser RA, Bossie CA, Gharabawi GM, Turner M. Patients 
with schizophrenia previously stabilized on conventional 
depot antipsychotics experience significant clinical improve-
ments following treatment with long-acting risperidone. Eur 
Psychiatry. 2004;19:219–225.
 25. Marinis TD, Saleem PT, Glue P, et  al. Switching to long-
acting injectable risperidone is beneficial with regard to 
clinical outcomes, regardless of previous conventional medi-
cation in patients with schizophrenia. Pharmacopsychiatry. 
2007;40:257–263.
 26. Fleischhacker WW. Second-generation antipsychotic long-
acting injections: systematic review. Br J Psychiatry Suppl. 
2009;52:S29–S36.
 27. Lambert M, De Marinis T, Pfeil J, Naber D, Schreiner A. 
Establishing remission and good clinical functioning in 
schizophrenia: predictors of best outcome with long-term 
risperidone long-acting injectable treatment. Eur Psychiatry. 
2010;25:220–229.
 28. Covell NH, McEvoy JP, Schooler NR, et al.; Schizophrenia 
Trials Network. Effectiveness of  switching from long-
acting injectable fluphenazine or haloperidol decanoate 
to long-acting injectable risperidone microspheres: an 
open-label, randomized controlled trial. J Clin Psychiatry. 
2012;73:669–675.
 29. McEvoy JP, Byerly M, Hamer RM, et  al. Effectiveness of 
paliperidone palmitate vs haloperidol decanoate for mainte-
nance treatment of schizophrenia: a randomized clinical trial. 
JAMA. 2014;311:1978–1987.
 30. Nielsen J, le Quach P, Emborg C, Foldager L, Correll CU. 
10-year trends in the treatment and outcomes of patients 
with first-episode schizophrenia. Acta Psychiatr Scand. 
2010;122:356–366.
 31. Kumar A, Strech D. Zuclopenthixol dihydrochloride for 
schizophrenia. Schizophr Bull. 2009;35:855–856.
 32. Pechlivanoglou P, Vehof J, van Agthoven M, de Jong-van 
den Berg LT, Postma MJ. Diffusion of a new drug: a com-
parative analysis of adoption, treatment complexity, and per-
sistence of risperidone long-acting injectable therapy in the 
Netherlands. Clin Ther. 2010;32:108–118.
 33. Li H, Rui Q, Ning X, Xu H, Gu N. A comparative study of 
paliperidone palmitate and risperidone long-acting injectable 
therapy in schizophrenia. Prog Neuropsychopharmacol Biol 
Psychiatry. 2011;35:1002–1008.
 34. Fleischhacker WW, Gopal S, Lane R, et  al. A randomized 
trial of paliperidone palmitate and risperidone long-acting 
injectable in schizophrenia. Int J Neuropsychopharmacol . 
2012;15:107–118.
